Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

underscored by a billion-dollar partnership with Sanofi. This collaboration is unique, focusing not on a specific drug but on ...

Per the Zacks analyst, amid a volatile macro environment, the company is making significant strides in Business AI initiatives ... are featuring today include Boston Scientific Corp. (BSX), Sanofi ...

AusBiotech is honoured to announce the establishment of the Depaz Oration, an annual keynote to be introduced at the AusBiotech Conference in 2025 in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Chase Orsello from Sanofi outlined the potential of AI and machine learning in improving CMC processes. These technologies ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

clinical-stage biotech company and was named Life Science AI champion at September’s Business Weekly Awards. In the latest ...